A Multicenter, Open-label Extended Access Program (EAP) of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.

Trial Profile

A Multicenter, Open-label Extended Access Program (EAP) of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 03 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
    • 02 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top